Metabolon (Durham, NC) a commercial-stage provider of biomarker discovery and analysis, closed a $13.1M Series D financing. Participants include Keating Capital, Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures and Fletcher Spaght.

NanoDetection Technology (Franklin, OH) a development-stage point-of-care diagnostic platform, closed a $2.3M Series A financing. Participants include CincyTech.

Allegro Diagnostics (Maynard, MA) a development-stage molecular diagnostics company focused on genomic tests for the diagnosis of lung cancer, closed a $5.4M Series A financing. Participants include Kodiak Venture Partners and Catalyst Health Ventures.

Precision Biopsy (Aurora, CO) a development-stage diagnostics company focused on advanced spectroscopy imaging and tissue biopsy for the diagnosis of prostate cancer, closed a $2.5M Series A financing. Participants include Allied Minds.

Crescendo Bioscience (San Francisco, CA) a commercial-stage molecular diagnostics company focused on quantitative biomarker tests for rheumatoid, closed a $31M Series C financing. Participants include Aeris Capital, Mohr Davidow Ventures and Kleiner Perkins Caufield & Byers.

NovaSom (Glen Burnie, MD) a commercial-stage medical device company focused on the diagnosis of obstructive sleep apnea, closed a $35M Series F financing. Participants include Safeguard Scientifics, TPG Biotech and Quaker BioVentures.

CardioDx (Palo Alto, CA) a commercial-stage cardiovascular molecular diagnostics company focused on coronary artery disease, cardiac arrhythmia and heart failure, closed a $60M Series E financing. Participants include Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artian Ventures and Briht Capital.

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series D financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Redmile Group.

Neuroptix (Acton, MA) a clinical-stage diagnostic platform company focused on a non-invasive predictive laser eye assay for the detection and diagnosis of Alzheimer’s, closed a $4M Series C financing. Participants include Inventages Venture Capital.

Microvisk Technologies (United Kingdom) a clinical-stage diagnostic company focused on prothrombin time assays designed to provide patients and clinicians with INR values used to aid in the correct dosage of anti-coagulation meds such as warfarin, closed a $9.5M Series C financing. Participants include Porton Capital, Oxford Technology Management, New Hill Management, Midven, Rainbow Seed Fund [...]

AssureRx Health (Mason, OH) a commercial-stage personalized medicine company focused on a pharmacogenetic platform for the determination of drug at selection and dosage, closed a $11M Series B financing. Participants include Claremont Creek Ventures, Sequoia Capital and Allos Ventures.

BioNanomatrix (Philadelphia, PA) commercial-stage developer of a nanochannel array chip, single-molecule imaging and analysis platform, closed a $23.3M Series B financing. Participants include Domain Associates, Gund Investment Corp., Battelle Ventures, Innovation Valley Partners and KT Venture Group.

Advanced Animal Diagnostics (Durham, NC) a commercial-stage developer of farm animal diagnostics focused on the detection of mastitis in dairy cows, closed a $11M Series B financing. Participants include Intersouth Partners and Novartis Venture Funds.